 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Steven Bair and Ajay Major.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.394 |
|
|
|
-
Allen J, Abbott D, Eskandar J, Bair SM, Haverkos B, Jasem J, Kamdar M, Major A. DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 Jan; 25(1):e26-e33.
Score: 0.219
-
Bock AM, Feng L, Chauhan A, Falchi L, Merryman RW, Godbole S, Kambhampati Thiruvengadam S, Jallouk AP, Major A, D'Angelo CR, Ayers A, Baron K, Farahat O, Shouse G, Danilov AV, Bair SM, Lunning MA, Bhaskar S, Herrera AF, Sawalha Y, Flowers CR, Crombie JL, Salles GA, Epperla N, Ahmed S. Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab. Blood Adv. 2026 Jun 05.
Score: 0.062
-
Chohan KL, Welkie RL, Godfrey J, Bair S, Falchi L, Kamdar M, Major A, Dixon W, Crombie J, Merryman R, Godbole S, Salles G, Farahat O, Ayers A, Chauhan A, Herrera A, Shouse G, Ahmed S, Sawalha Y. Clinical outcomes of CD3xCD20 bispecific antibodies in patients with central nervous system involvement by lymphoma. Blood Cancer J. 2026 May 22; 16(1).
Score: 0.061
-
Haverkos B, Zain J, Kamdar M, Neuwelt A, Davila E, Bradeen X, Major A, Bair S, Jasem J, Smith C, Abbott D, Porcu P. Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial. Blood Adv. 2024 02 13; 8(3):708-711.
Score: 0.052
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|